Print Page      Close Window     

Investors

Developing transformative therapies targeting cancer

Founded 20 years ago, Seattle Genetics was built on a foundation of scientific innovation, rigorous research and drug development practices, as well as a passion for helping patients. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer has resulted in an approved drug for multiple indications and a robust pipeline of innovative programs in clinical development for a range of hematologic and solid tumors.

Recent News

  • Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer MORE
  • Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference MORE
  • Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting MORE

VIEW ALL NEWS

$66.85

 0.24 (0.36%)

06/22/18  4:00 p.m. ET

NASDAQ | SGEN (Common Stock)

High$67.29
Volume952,263
Low$66.25
Mkt Cap$10,577,303,012

Data provided by Nasdaq. Minimum 15 minutes delay

Seattle Genetics Fast Facts

NASDAQSGEN

Common Stock CUSIP812578 102

Fiscal Year Jan. 1 - Dec. 31

State IncorporatedDelaware

Transfer Agent Computershare

STAY CONNECTED

Investor Contact

Peggy Pinkston
Vice President, Investor Relations
investors@seagen.com
425-527-4160

Email Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Get email alerts